Please try another search
For the nine months ended 30 September 2017, Ocera Therapeutics Inc revenues decreased from $97K to $0K. Net loss decreased 12% to $19.1M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Research and development - decrease of 16% to $10.4M (expense), Stock-based Compensation in SGA decrease of 18% to $2.2M (expense).
Period Ending: | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0 | 0.51 |
Gross Profit | ||||
Operating Income | -6.08 | -5.91 | -6.43 | -4.9 |
Net Income | -6.27 | -6.13 | -6.68 | -5.15 |
Period Ending: | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 |
---|---|---|---|---|
Total Assets | 15.59 | 21.68 | 26.59 | 29.64 |
Total Liabilities | 11.74 | 12.42 | 13.07 | 13.9 |
Total Equity | 3.85 | 9.27 | 13.52 | 15.74 |
Period Ending: | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | -16.16 | -10.88 | -6.43 | -22.1 |
Cash From Investing Activities | 3.75 | 3.35 | 3.75 | 3.62 |
Cash From Financing Activities | 2.15 | 3.08 | 3.25 | 7.17 |
Net Change in Cash | -10.26 | -4.45 | 0.57 | -11.31 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review